This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)
by Zacks Equity Research
Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.
Boston Scientific Wins CE Mark for Vercise Gevia DBS System
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System.
Boston Scientific (BSX) Up 4.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific Trades Up on Strong Q1 amid Recall Issues
by Zacks Equity Research
On May 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Boston Scientific (BSX) BT Study on Asthma Results Positive
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently unveiled positive outcome from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study.
Boston Scientific's Symetis Buyout Boosts Structural Heart
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently completed the acquisition of Switzerland-based Symetis SA.
Boston Scientific Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of Natick, MA-based Boston Scientific Corporation (BSX) reached a new 52-week high of $26.76 on May 16, eventually closing a bit lower at $26.48.
Boston Scientific (BSX) Misses on Q1 Earnings, Updates View
by Zacks Equity Research
Boston Scientific Corporation (BSX) posted adjusted EPS 29 cents in the first quarter, up 5.3% from the year-ago quarter.
Boston Scientific (BSX): Beats on Q1 Sales, Misses Earnings
by Zacks Equity Research
Boston Scientific's adjusted earnings of 29 cents per share missed the Zacks Consensus Estimate in the first quarter.
Will Boston Scientific (BSX) Surprise this Earnings Season?
by Zacks Equity Research
Boston Scientific Corporation (BSX) is scheduled to report first-quarter 2017 results before the opening bell on Apr 27.
Boston Scientific's Emerging Markets Grow Amid Currency Woes
by Zacks Equity Research
On Apr 11 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Boston Scientific (BSX) Inks Agreement to Acquire Symetis SA
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently signed a definitive agreement to acquire Switzerland-based Symetis SA for $435 million in up-front cash, in a bid to fortify its structural heart business in Europe.
Obamacare Repeal Vote Looms: What Investors Need to Know
by Madeleine Johnson
Investors' eyes will be focused on Congress today, as the House is scheduled to vote on the American Healthcare Act (AHCA). Whether you think it???s "Obamacare Lite" or "dead on arrival" like Sen. Rand Paul, the AHCA has certainly made an impact on Wall Street, as well as the entire healthcare industry since its announcement.
Your Guide to the Stock Winners & Losers of Trump's Obamacare Replacement Bill
by Madeleine Johnson
Whether you think it???s "Obamacare Lite," "Obamacare 2.0," "dead on arrival" like Rand Paul, or you actually like the bill, the American Healthcare Act (AHCA) has certainly made an impact on the entire healthcare industry since its announcement. Who are the stock winners and losers so far? And who will be affected if it's passed?
4 Big Winners of Trump's Healthcare Plan
by Swarup Gupta
The new healthcare legislation has its own sets of winners and losers.
Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View
by Zacks Equity Research
Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 30 cents, up 15.4% from the year-ago adjusted number.
Boston Scientific (BSX) Beats on Earnings & Revenues in Q4
by Zacks Equity Research
Boston Scientific (BSX) has posted positive results with both its top line and bottom line beating the Zacks Consensus Estimate.
5 Stocks with Spectacular Earnings Charts
by Tracey Ryniec
These 5 companies have perfect earnings beat records for the last 5 years.
Medical Product Earnings Due on Feb 2: BDX, BSX, IDXX, ATHN
by Zacks Equity Research
The medical sector is likely to see 2.9% earnings growth on 5.7% higher revenues in the quarter.
Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2.
Boston Scientific Down on Risks; Innovations Raise Hope
by Zacks Equity Research
On Dec 27 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Boston Scientific Acquires Neovasc to Boost Heart Business
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently completed the acquisition of specialty medical device company Neovasc Inc.'s (NVCN) tissue processing technology.
Boston Scientific (BSX) Inks $75 Million Deal with Neovasc
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently inked a deal with specialty medical device company Neovasc Inc.